Literature DB >> 30624309

High Global Burden and Costs of Bacterial Vaginosis: A Systematic Review and Meta-Analysis.

Kathryn Peebles, Jennifer Velloza, Jennifer E Balkus, R Scott McClelland, Ruanne V Barnabas.   

Abstract

BACKGROUND: Bacterial vaginosis (BV) is the most common vaginal infection among women of reproductive age and is associated with important adverse health outcomes. Estimates of the burden of BV and associated costs are needed to inform research priorities.
METHODS: We conducted a systematic review and meta-analysis of global BV prevalence among reproductive-aged women in the general population. We searched PubMed and Embase and used random effects models to estimate BV prevalence by global regions. We estimated the direct medical costs of treating symptomatic BV. Assuming a causal relationship, we also estimated the potential costs of BV-associated preterm births and human immunodeficiency virus cases in the United States.
RESULTS: General population prevalence of BV is high globally, ranging from 23% to 29% across regions (Europe and Central Asia, 23%; East Asia and Pacific, 24%; Latin America and Caribbean, 24%; Middle East and North Africa, 25%; sub-Saharan Africa, 25%; North America, 27%; South Asia, 29%). Within North America, black and Hispanic women have significantly higher (33% and 31%, respectively) prevalence compared with other racial groups (white, 23%; Asian, 11%; P < 0.01). The estimated annual global economic burden of treating symptomatic BV is US $4.8 (95% confidence interval, $3.7-$6.1) billion. The US economic burden of BV is nearly tripled when including costs of BV-associated preterm births and human immunodeficiency virus cases.
CONCLUSIONS: The BV prevalence is high globally, with a concomitant high economic burden and marked racial disparities in prevalence. Research to determine the etiology of BV and corresponding prevention and sustainable treatment strategies are urgently needed to reduce the burden of BV among women. Additionally, the exceptionally high cost of BV-associated sequelae highlights the need for research to understand potential causal linkages between BV and adverse health outcomes.

Entities:  

Mesh:

Year:  2019        PMID: 30624309     DOI: 10.1097/OLQ.0000000000000972

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   2.830


  65 in total

Review 1.  The microbiome and gynaecological cancer development, prevention and therapy.

Authors:  Paweł Łaniewski; Zehra Esra Ilhan; Melissa M Herbst-Kralovetz
Journal:  Nat Rev Urol       Date:  2020-02-18       Impact factor: 14.432

Review 2.  Lessons from Suppressive Therapy and Periodic Presumptive Treatment for Bacterial Vaginosis.

Authors:  Jennifer E Balkus; Kayla A Carter; R Scott McClelland
Journal:  Curr Infect Dis Rep       Date:  2019-08-31       Impact factor: 3.725

3.  Biogenic Amines Increase the Odds of Bacterial Vaginosis and Affect the Growth of and Lactic Acid Production by Vaginal Lactobacillus spp.

Authors:  Joanna-Lynn C Borgogna; Michelle D Shardell; Savannah G Grace; Elisa K Santori; Benjamin Americus; Zhong Li; Alexander Ulanov; Larry Forney; Tiffanie M Nelson; Rebecca M Brotman; Jacques Ravel; Carl J Yeoman
Journal:  Appl Environ Microbiol       Date:  2021-04-27       Impact factor: 4.792

4.  Randomized Trial of Lactin-V to Prevent Recurrence of Bacterial Vaginosis.

Authors:  Craig R Cohen; Michael R Wierzbicki; Audrey L French; Sheldon Morris; Sara Newmann; Hilary Reno; Lauri Green; Steve Miller; Jonathan Powell; Thomas Parks; Anke Hemmerling
Journal:  N Engl J Med       Date:  2020-05-14       Impact factor: 91.245

5.  Association between bacterial vaginosis and fecundability in Kenyan women planning pregnancies: a prospective preconception cohort study.

Authors:  Erica M Lokken; Lisa E Manhart; John Kinuthia; James P Hughes; Clayton Jisuvei; Khamis Mwinyikai; Charles H Muller; Kishor Mandaliya; Walter Jaoko; R Scott McClelland
Journal:  Hum Reprod       Date:  2021-04-20       Impact factor: 6.918

6.  Asymptomatic Bacterial Vaginosis: To Treat or Not to Treat?

Authors:  Christina A Muzny; Jane R Schwebke
Journal:  Curr Infect Dis Rep       Date:  2020-11-13       Impact factor: 3.725

7.  Perceived Stress and Molecular Bacterial Vaginosis in the National Institutes of Health Longitudinal Study of Vaginal Flora.

Authors:  Rodman Turpin; Natalie Slopen; Joanna-Lynn C Borgogna; Carl J Yeoman; Xin He; Ryan S Miller; Mark A Klebanoff; Jacques Ravel; Rebecca M Brotman
Journal:  Am J Epidemiol       Date:  2021-11-02       Impact factor: 4.897

Review 8.  Protection and Risk: Male and Female Genital Microbiota and Sexually Transmitted Infections.

Authors:  Susan Tuddenham; Jacques Ravel; Jeanne M Marrazzo
Journal:  J Infect Dis       Date:  2021-06-16       Impact factor: 5.226

9.  Treatment of Male Sexual Partners of Women With Bacterial Vaginosis: A Randomized, Double-Blind, Placebo-Controlled Trial.

Authors:  Jane R Schwebke; Shelly Y Lensing; Jeannette Lee; Christina A Muzny; Angela Pontius; Nicole Woznicki; Tina Aguin; Jack D Sobel
Journal:  Clin Infect Dis       Date:  2021-08-02       Impact factor: 9.079

10.  Gardnerella vaginalis promotes group B Streptococcus vaginal colonization, enabling ascending uteroplacental infection in pregnant mice.

Authors:  Nicole M Gilbert; Lynne R Foster; Bin Cao; Yin Yin; Indira U Mysorekar; Amanda L Lewis
Journal:  Am J Obstet Gynecol       Date:  2020-11-26       Impact factor: 8.661

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.